The VALOR Study – A Clinical Trial for People Living with SOD1-ALS

Biogen is conducting a clinical trial to evaluate the safety and potential efficacy of an investigational drug for people with Amyotrophic Lateral Sclerosis (ALS) carrying a SOD1 gene mutation.

Study Duration

  • 32-36 weeks, including:
  • 4-week screening
  • 24-week study treatment period
  • 4 to 8-week follow-up period

Investigational Drug

  • Tofersen (BIIB067), an antisense oligonucleotide (ASO)
  • Designed to reduce the amount of SOD1 protein in the body
  • Given intrathecally, through a lumbar puncture

Key Eligibility Criteria

  • 18 years of age or older
  • Have weakness caused by ALS
  • Agree to genetic testing for the SOD1 mutation

All Eligible Participants Will Receive At No Cost

  • Comprehensive study-related health evaluations and assessments, including genetic testing
  • Investigational drug or placebo
  • All study-related visits and care

Assistance with travel and accommodations, and reimbursement for study-related expenses may also be available. See if you may be eligible and view our study locations.


Share

Related news

Swimming the Catalan coast to raise funds for TRICALS
Swimming the Catalan coast to raise funds for TRICALS
To raise funds for TRICALS, Daniel Rossinés has taken on an epic […]
CENTAUR phase 2 trial reveals promising results
CENTAUR phase 2 trial reveals promising results
New findings from the CENTAUR trial show that the drug ‘sodium phenylbutyrate–taurursodiol’ […]
Current developments in clinical trial design and conduct
Current developments in clinical trial design and conduct
Over 70 compounds have been evaluated by clinical studies, yet Riluzole is […]
Reforming clinical studies for ALS
Reforming clinical studies for ALS
In order to find new treatments for ALS, our current strategy for […]